Neratinib enhances the efficacy of CDK4/6 inhibitor plus endocrine therapy in HR+/HER2-low breast cancer cell line ZR-75-1 via hsa-miR-23a-5p

Authors: Liushan Chen, Lingling Ye, Yuqi Liang, Wei Luo, Qian Zuo, Ping Huang, Yuyu Hu, Yan Dai, Yingchao Wu, Qianqian Guo, Qianjun Chen

Source: Scientific Reports, Vol 14, Iss 1, Pp 1-16 (2024)

Subject Terms: Neratinib, HER2 mRNA stability, HR+/HER2-low, CDK4/6 inhibitor, Endocrine therapy, Hsa-miR-23a-5p, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/8c5ec51c9bf541d782ffbd12bcb3580a

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma

Authors: Martina Napolitano, Lucia Trudu, Enrica Martinelli, Chiara Santini, Massimo Dominici, Federica Bertolini

Source: Cancer Reports, Vol 8, Iss 1, Pp n/a-n/a (2025)

Subject Terms: head and neck, HER2 targeted therapy, neratinib, precision medicine, salivary duct carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2573-8348

Access URL: https://doaj.org/article/aa47aebe2fcb48acbd56af12d654fe5a

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan

Authors: Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Source: Frontiers in Oncology, Vol 14 (2025)

Subject Terms: breast cancer, precision oncology, cancer genomics, HER2 antibody-drug conjugates (HER2 ADC), trastuzumab deruxtecan, neratinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1484750/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/6af26a460ffe43a382c2101e7ed95639

Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma

Authors: Ghassan K. Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A. Piha-Paul, Joseph S. Light, Scott Sherrin, Amin Yaqubie, Alison Clemens O’Neill, James J. Harding, Raed Al-Rajabi, Crystal S. Denlinger, Pablo Cano, Albert S. Cornelius, Eileen M. O'Reilly, Daniel DiPrimeo, Lisa D. Eli, John D. Gordan, David B. Solit

Source: Liver Cancer, Pp 1-10 (2024)

Subject Terms: neratinib, fibrolamellar carcinoma, summit phase 2 basket study, pan-her kinase inhibition, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://beta.karger.com/Article/FullText/540290; https://doaj.org/toc/1664-5553

Access URL: https://doaj.org/article/060277f2d7054affa161c9c60698ca95

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

Authors: Piha-Paul, S.A. ^{1, ∗}, Tseng, C. ¹, Tran, H.T. ², Naing, A. ¹, Dumbrava, E.E. ¹, Karp, D.D. ¹, Rodon, J. ^{1, 3}, Yap, T.A. ^{1, 3, 4}, Raghav, K.P. ⁵, Damodaran, S. ⁶, Le, X. ², Soliman, P.T. ⁷, Lim, J. ⁸, Meric-Bernstam, F. ^{1, 3, 9}

Source: In ESMO Open February 2025 10(2)

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Authors: Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Johanna Gaubatz, Justine Meiller, Fiona O'Neill, Lorraine O'Driscoll, Mattia Cremona, Bryan T Hennessy, Lisa D Eli, John Crown, Denis M Collins

Source: Translational Oncology, Vol 49, Iss , Pp 102073- (2024)

Subject Terms: Breast cancer, HER2-positive, Targeted therapies, Tyrosine kinase inhibitors, Neratinib, Dasatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1936523324002006; https://doaj.org/toc/1936-5233

Access URL: https://doaj.org/article/80c2e8e9bf2e4172bafb263c57f5769f

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer

Authors: Majid Momeny, Mari Tienhaara, Mukund Sharma, Deepankar Chakroborty, Roosa Varjus, Iina Takala, Joni Merisaari, Artur Padzik, Andreas Vogt, Ilkka Paatero, Klaus Elenius, Teemu D Laajala, Kari J Kurppa, Jukka Westermarck

Source: EMBO Molecular Medicine, Vol 16, Iss 7, Pp 1603-1629 (2024)

Subject Terms: Non-genetic Drug Tolerance, Lapatinib, Neratinib, BCI, FOXM1, Medicine (General), R5-920, Genetics, QH426-470

File Description: electronic resource

Relation: https://doaj.org/toc/1757-4684

Access URL: https://doaj.org/article/709f9a596c0c46e4951cbcebf8781895

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

Authors: Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile

Source: Breast Cancer Research, Vol 26, Iss 1, Pp 1-13 (2024)

Subject Terms: Metastatic breast cancer, ctDNA HER2 amplification, Clinical trial, Neratinib + t-DM1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1465-542X

Access URL: https://doaj.org/article/c30874be81f04b78be67858f937fdb82

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database

Authors: Yunhe Fan, Teng Wu, Pengyang Xu, Chuanli Yang, Jie An, Haijia Zhang, Mureed Abbas, Xiushan Dong

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: neratinib, FAERS, adverse drug events, disproportionality methods, safety signal, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1425171/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/1a826a6e83134d7bb805c4eb1ca70c14

Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in HER2‐positive breast cancer—A pilot study

Authors: Joanne Bowen, Sofia Braga, Valeria Dal Zotto, John Finnie, Daniel DiPrimeo, Blaire Cooke, Georg F. Bischof, Alvin Wong, Jack A. Di Palma

Source: Physiological Reports, Vol 12, Iss 16, Pp n/a-n/a (2024)

Subject Terms: colonoscopy study, diarrhea, HER2‐positive breast cancer, neratinib, rat model, Physiology, QP1-981

File Description: electronic resource

Relation: https://doaj.org/toc/2051-817X

Access URL: https://doaj.org/article/4ac23f911fbd43ba915c155b47741514

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

Authors: Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T

Source: Breast Cancer: Targets and Therapy, Vol Volume 15, Pp 785-799 (2023)

Subject Terms: tnbc, erlotinib, neratinib, cisplatin, drug combination, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/therapeutic-advantage-of-targeting-prmt5-in-combination-with-chemother-peer-reviewed-fulltext-article-BCTT; https://doaj.org/toc/1179-1314

Access URL: https://doaj.org/article/f6665d7752f94fd2bf4c6b9c1b4d5cee

Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report

Authors: Nora Asper, Kersten Sven Roth, Thomas Frank Hany, Sacha Pierre Salzberg, Marianne Tinguely, Yannick Kadvany, Andreas Trojan

Source: Case Reports in Oncology, Vol 16, Iss 1, Pp 1500-1507 (2023)

Subject Terms: erbb2, salivary duct carcinoma, neratinib, electronically captured patient-reported outcomes, case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://beta.karger.com/Article/FullText/535097; https://doaj.org/toc/1662-6575

Access URL: https://doaj.org/article/b4dffc13b4574f70850033b41d67241a

Neratinib for HER2-positive breast cancer with an overlooked option

Authors: Liting Guo, Weiwei Shao, Chenfei Zhou, Hui Yang, Liu Yang, Qu Cai, Junqing Wang, Yan Shi, Lei Huang, Jun Zhang

Source: Molecular Medicine, Vol 29, Iss 1, Pp 1-23 (2023)

Subject Terms: Neratinib, Breast cancer, HER2, Central nervous system metastasis, Therapeutics. Pharmacology, RM1-950, Biochemistry, QD415-436

File Description: electronic resource

Relation: https://doaj.org/toc/1528-3658

Access URL: https://doaj.org/article/22b15f57c4484be887531f03bead5f7f

Analysis of Natural Bioactive Compounds in Plant, Food, and Pharmaceutical Products Using Chromatographic Techniques

Contributors: Shakeel, Faiyaz

Subject Terms: C. indica, propolis, GC-MS, antibacterial, bioactive compounds, chemical composition, AGREE, Curcuma longa, curcumin, nanoemulsion, greener HPLC, validation, lavender oil, cytotoxic, scolicidal, Musca domestica, acaricide, capillary electrophoresis, fluorescence detection, honey, sugars, breast cancer, liquid chromatography, bioanalytical methods, neratinib, naringenin, dosage form, HPLC, pterostilbene, solubility, stability, lamb meat, heterocyclic aromatic amines, roasted, spices, olive leaves, extraction, optimization, ultrasound, polyphenols, flavonoids, antioxidant, Haberlea rhodopensis, myconoside, hispidulin 8-C-(6-O-acetyl-2″-O-syringoyl-β-glucopyranoside), GLUT1 transporter, estrogen receptor and MYST acetyltransferase, Gymnosperma glutinosum, cosmetology, skin care, antioxidants, bisabolol, Research and information: general, Chemistry, Analytical chemistry

File Description: application/octet-stream

Access URL: https://directory.doabooks.org/handle/20.500.12854/128637
https://mdpi.com/books/pdfview/book/8089

Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient’s response to conventional and novel therapies

Authors: Liting Liu, Min Wu, Anni Huang, Chun Gao, Yifan Yang, Hong Liu, Han Jiang, Long Yu, Yafei Huang, Hui Wang

Source: Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-21 (2023)

Subject Terms: Cervical cancer, PDX, Chemotherapy, Adoptive T-cell therapy, Neratinib, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/1479-5876

Access URL: https://doaj.org/article/4e5b1ded629d43c5ab536922f1d08de7

Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: A dual-death therapy for triple negative breast cancer

Authors: Ghadi, Rohan ^{a, 1}, Pandey, Pawan Kumar ^{a, 1}, Gabhale, Akash ^a, Wadikar, Aaradhya ^a, Dharshini, M. ^a, Kuche, Kaushik ^a, Date, Tushar ^a, Jain, Sanyog ^{a, ⁎}

Source: In International Journal of Pharmaceutics 15 December 2023 648

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

Authors: Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A. García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanne McCulloch, Sara A. Hurvitz, Carlos H. Barcenas

Source: Breast, Vol 67, Iss , Pp 94-101 (2023)

Subject Terms: Neratinib, Tyrosine kinase inhibitor, HER2-positive, Breast cancer, Early stage, Diarrhea prophylaxis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0960977622001953; https://doaj.org/toc/1532-3080

Access URL: https://doaj.org/article/59dce946fa4342e6b9fbbf464f2e5a40

Effects of neratinib on angiogenesis and the early stage of the embryo using chicken embryo as a model

Authors: Hadeel Kheraldine, Arij Fouzat Hassan, Hashim Alhussain, Hamda Al-Thawadi, Semir Vranic, Ala-Eddin Al Moustafa

Source: Biomolecules & Biomedicine (2023)

Subject Terms: Neratinib, angiogenesis, embryogenesis, chorioallantoic membrane (CAM), tyrosine kinase inhibitor (TKI), Biology (General), QH301-705.5

File Description: electronic resource

Relation: https://www.bjbms.org/ojs/index.php/bjbms/article/view/9869; https://doaj.org/toc/2831-0896; https://doaj.org/toc/2831-090X

Access URL: https://doaj.org/article/1d8526b072644190ab3630964e85c81f

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer

Authors: Salkeni MA, Rizvi W, Hein K, Higa GM

Source: Breast Cancer: Targets and Therapy, Vol Volume 13, Pp 539-557 (2021)

Subject Terms: ado-trastuzumab emtansine, erbb, fam-trastuzumab deruxtecan, her2, lapatinib, margetuximab, neratinib, neu, pertuzumab, phesgo, trastuzumab, tucatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/neu-perspectives-therapies-and-challenges-for-metastatic-her2-positive-peer-reviewed-fulltext-article-BCTT; https://doaj.org/toc/1179-1314

Access URL: https://doaj.org/article/46bae7ee4c0f4a189823d454f63a5b4d

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Authors: Chilà G, Guarini V, Galizia D, Geuna E, Montemurro F

Source: Drug Design, Development and Therapy, Vol Volume 15, Pp 2711-2720 (2021)

Subject Terms: neratinib, tyrosine kinase inhibitors, breast cancer, her2, metastasis, randomized clinical trial, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.dovepress.com/the-clinical-efficacy-and-safety-of-neratinib-in-combination-with-cape-peer-reviewed-fulltext-article-DDDT; https://doaj.org/toc/1177-8881

Access URL: https://doaj.org/article/e982f3f4d0654161b7081fa673fd847a